Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.96 +0.26 (+0.77%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
The company reported lighter-than-expected declines due to Keytruda and Gardasil. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
Both GSK and Roche experienced declining Covid-related sales in the first quarter. 
Via Investor's Business Daily
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance
Via Benzinga
This Favorable Sign Appears On GSK's Chart
Via Benzinga
This House of Representative Just Sold Up To $100K In GSK Stock
Via Benzinga
Was This Acquisition a Savvy Play by This Big Pharma Stock?
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health. 
Via The Motley Fool
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a  
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases. 
Via The Motley Fool
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
Via Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
Why Shares of Bellus Health Skyrocketed This Week
The company has received a buyout offer from GSK. 
Via The Motley Fool
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
From BELLUS Health Inc.
Via Business Wire
Why BELLUS Health Stock Is Rocketing Higher Today
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
Shares of its takeover candidate nearly doubled on the news. 
Via Investor's Business Daily
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs 
Via Benzinga
Why Is Bellus Health (BLU) Stock Up 98% Today?
Bellus Health (BLU) stock is taking off on Tuesday after the company announced a $2 billion acquisition deal with GSK (GSK). 
Via InvestorPlace
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
Via Benzinga
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
There's such a big need in preventing RSV that multiple companies should be big winners. 
Via The Motley Fool
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
The company bulks up its pipeline by regaining the rights to two of its clinical programs. 
Via The Motley Fool
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a... 
Via Benzinga
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will... 
Via Newsfile
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging
While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Top Biotech Stocks to Buy in April
Right now you can pick up these stocks on the dip. 
Via The Motley Fool
Could This Move by Johnson & Johnson Equal Billions for Moderna?
An RSV vaccine could be a driver of blockbuster revenue. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.